• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Amneal Pharmaceuticals Inc.

    11/17/25 3:06:30 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMRX alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001316851
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Amneal Pharmaceuticals, Inc.
    SEC File Number
    001-38485
    Address of Issuer
    400 Crossing Boulevard
    Bridgewater
    NEW JERSEY
    08807
    Phone
    (908) 947-3120
    Name of Person for Whose Account the Securities are To Be Sold
    Nark Ted C
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Charles Schwab Corp.
    3000 Schwab Way
    Westake � TX � 76262
    50000591250.0031436292011/17/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common08/28/2019Open Market PurchaseIssuerCheckbox not checked5000008/28/2019Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    These shares are being sold out of the NARK LIVING TRUST U/A DTD 06/10/2003
    Date of Notice
    11/17/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    THEODORE C NARK

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $AMRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMRX

    DatePrice TargetRatingAnalyst
    12/9/2025$15.00Overweight
    Barclays
    6/6/2025$12.00Buy
    Goldman
    2/24/2025$9.00 → $12.00Neutral → Overweight
    Analyst
    9/6/2024$9.00Underweight → Neutral
    JP Morgan
    More analyst ratings

    $AMRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Amneal Launches Bimatoprost Ophthalmic Solution, 0.01%

    BRIDGEWATER, N.J., April 09, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") today announced the launch of bimatoprost ophthalmic solution 0.01% (2.5 mL, 5 mL and 7.5 mL). The product is the generic equivalent of LUMIGAN® (bimatoprost ophthalmic solution) 0.01%, whose design is a trademark of Allergan, Inc., an AbbVie company. Bimatoprost ophthalmic solution 0.01% is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. "We are pleased to bring another key ophthalmic therapy to our Affordable Medicines portfolio," said Dr. Srinivas Kone, Senior Vice President, Chie

    4/9/26 8:00:00 AM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amneal to Report First Quarter 2026 Results on May 1, 2026

    BRIDGEWATER, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), today announced that the Company will release its first quarter 2026 financial results on Friday, May 1, 2026, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET. The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. Individuals may register for the webcast by clicking the link here. To access the call through a conference line, dial 1 (833) 461-5787 (in the U.S.) or for a list of toll-free international numbers, visit this here. The access

    4/7/26 4:01:00 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson's Awareness Month

    BRIDGEWATER, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NASDAQ:AMRX) today announced donations totaling $2 million to multiple patient assistance foundations supporting individuals living with Parkinson's disease (PD) in recognition of Parkinson's Awareness Month. These contributions reflect Amneal's ongoing commitment to expanding access to essential medicines and supporting patient care, education, and advocacy for the Parkinson's community. Every six minutes, someone in the United States is diagnosed with Parkinson's disease, underscoring the growing impact of a condition that affects more than 10 million people worldwide. As the

    4/7/26 8:00:00 AM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Amneal Pharmaceuticals with a new price target

    Barclays initiated coverage of Amneal Pharmaceuticals with a rating of Overweight and set a new price target of $15.00

    12/9/25 8:42:32 AM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Amneal Pharmaceuticals with a new price target

    Goldman initiated coverage of Amneal Pharmaceuticals with a rating of Buy and set a new price target of $12.00

    6/6/25 8:33:10 AM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amneal Pharmaceuticals upgraded by Analyst with a new price target

    Analyst upgraded Amneal Pharmaceuticals from Neutral to Overweight and set a new price target of $12.00 from $9.00 previously

    2/24/25 7:02:03 AM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Amneal Pharmaceuticals Inc.

    SCHEDULE 13G/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)

    3/26/26 3:43:45 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Amneal Pharmaceuticals Inc.

    DEFA14A - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)

    3/25/26 4:16:09 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Amneal Pharmaceuticals Inc.

    DEF 14A - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)

    3/25/26 4:15:42 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by Patel Chintu

    4/A - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)

    3/27/26 4:20:46 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 4 filed by Patel Chirag K.

    4/A - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)

    3/27/26 4:19:46 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Co-CEO Patel Chintu converted options into 886,468 shares and covered exercise/tax liability with 361,980 shares, increasing direct ownership by 61% to 1,388,521 units (SEC Form 4)

    4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)

    3/5/26 4:52:25 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRX
    Leadership Updates

    Live Leadership Updates

    View All

    Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson's Awareness Month

    BRIDGEWATER, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NASDAQ:AMRX) today announced donations totaling $2 million to multiple patient assistance foundations supporting individuals living with Parkinson's disease (PD) in recognition of Parkinson's Awareness Month. These contributions reflect Amneal's ongoing commitment to expanding access to essential medicines and supporting patient care, education, and advocacy for the Parkinson's community. Every six minutes, someone in the United States is diagnosed with Parkinson's disease, underscoring the growing impact of a condition that affects more than 10 million people worldwide. As the

    4/7/26 8:00:00 AM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600

    NEW YORK, Jan. 27, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600: S&P SmallCap 600 constituent TTM Technologies Inc. (NASD: TTMI) will replace Civitas Resources Inc. (NYSE:CIVI) in the S&P MidCap 400, and Amneal Pharmaceuticals Inc. (NASD: AMRX) will replace TTM Technologies in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 30. S&P SmallCap 600 constituent SM Energy Co. (NYSE:SM) is acquiring Civitas Resources in a deal expected to be completed soon, pending final closing conditions. SM Energy will remain in the S&P SmallCap 600 post-merger.Dutch Bros Inc. (NYSE:BROS) will replace Potlatc

    1/27/26 6:02:00 PM ET
    $AEIS
    $AHR
    $AMRX
    Industrial Machinery/Components
    Technology
    Real Estate Investment Trusts
    Real Estate

    Amneal Donates $1.5 Million to Support Patients During Parkinson's Awareness Month

    Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), a global biopharmaceutical company, today announced donations totaling $1.5 million to multiple patient assistance foundations that support individuals living with Parkinson's disease in honor of Parkinson's Awareness Month. These contributions underscore Amneal's ongoing commitment to the Parkinson's community by supporting patient care, education, and advocacy—and helping patients and caregivers navigate the unique challenges of living with the disease. Parkinson's disease affects more than 10 million people around the world. The progressive nature of the disease, along with the cost of treatment, often places signif

    4/11/25 8:00:00 AM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRX
    Financials

    Live finance-specific insights

    View All

    Amneal to Report First Quarter 2026 Results on May 1, 2026

    BRIDGEWATER, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), today announced that the Company will release its first quarter 2026 financial results on Friday, May 1, 2026, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET. The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. Individuals may register for the webcast by clicking the link here. To access the call through a conference line, dial 1 (833) 461-5787 (in the U.S.) or for a list of toll-free international numbers, visit this here. The access

    4/7/26 4:01:00 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amneal Reports Fourth Quarter and Full Year 2025 Financial Results

    ‒ Full Year 2025 Performance Met or Exceeded All Guidance Metrics and 2026 Reflects Another Year of Growth – ‒ Q4 2025 Net Revenue of $814 million; GAAP Net Income of $35 million; Diluted Income per Share of $0.11 ‒ ‒ Q4 2025 Adjusted Net Income of $68 million, Adjusted EBITDA of $175 million; Adjusted Diluted EPS of $0.21 ‒ ‒ Full Year 2025 Net Revenue of $3.02 billion; GAAP Net Income of $72 million; Diluted Income per Share of $0.22 ‒ ‒ Full Year 2025 Adjusted Net Income of $269 million; Adjusted EBITDA of $688 million; Adjusted Diluted EPS of $0.83 ‒ ‒ Provides 2026 Financial Guidance of $3.05 to $3.15 billion in net revenue, $720 to $760 million in Adjusted EBITDA, and $0.93 to $1.0

    2/27/26 6:00:00 AM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026

    BRIDGEWATER, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), today announced that the Company will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET. The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. Individuals may register for the webcast by clicking the link here. To access the call through a conference line, dial 1 (833) 470-1428 (in the U.S.) or for a list of toll-free international numbers, visit t

    1/27/26 8:00:00 AM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Amneal Pharmaceuticals Inc.

    SC 13G/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)

    11/14/24 4:11:34 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Amneal Pharmaceuticals Inc.

    SC 13D/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)

    10/31/24 6:51:29 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Amneal Pharmaceuticals Inc. (Amendment)

    SC 13D/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)

    5/13/24 4:15:28 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care